Company Colinz Laboratories Limited

COLINZ6

INE923C01011

Pharmaceuticals

Delayed Bombay S.E. 02:12:39 2026-09-15 EDT			5-day change	1st Jan Change
72.55 ^INR	+0.07%		-0.62%	+35.28%

07-30	Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
06-17	Annjana Dugar, Likhitta Dugar and Antariksh Dugar executed of Share Purchase Agreement to acquire an additional 34.56% stake in Colinz Laboratories Limited from Vijaya Mani for INR 43.5 million,	CI

Business description: Colinz Laboratories Limited

Colinz Laboratories Ltd. is an India-based company that is engaged in the manufacturing and marketing of pharmaceutical formulations, particularly in the gynecological sector. It is engaged in the manufacturing and marketing various allopathic, ayurvedic, and nutraceuticals pharmaceutical formulations in the dosage forms of tablets, capsules, liquid orals and ointments, among others. The company has specialized products for Gynecology, cardiology, gastroenterology, and others. Its oncology products include imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, and doxorubicin. Its Ayurvedic products include anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, and memory boosters. Its nutraceuticals products include spirulina tabs/caps, spirulina with vitamins & minerals, omega 3 fatty acid caps in softgel, codliver oil with vitamin caps in soft gel, collagen, and glucosamine & chondroitin tabs.

Number of employees: 62

Sales by Activity: Colinz Laboratories Limited

Fiscal Period: March	2022 (INR)	2023 (INR)	2024 (INR)	2025 (INR)	2026 (INR)
Manufacturing Pharmaceutical Formulations	69.74M	71.55M	70.3M	65.28M	61.36M

See all business segments

Geographical breakdown of sales: Colinz Laboratories Limited

Fiscal Period: March	2022 (INR)	2023 (INR)	2024 (INR)	2025 (INR)	2026 (INR)
India	69.74M	71.55M	70.3M	65.28M	61.36M

See all geographic segments

Executive Committee: Colinz Laboratories Limited

Manager	Title	Age	Since
Narayan Kutty Menon CEO	Chief Executive Officer	74	-
Ganesh Chitte DFI	Director of Finance/CFO	-	2019-05-19
Falguni Kumawat CMP	Compliance Officer	-	2025-11-30

See COLINZ LABORATORIES LIMITED governance

Composition of the Board of Directors: Colinz Laboratories Limited

Director	Title	Age	Since
Narayan Kutty Menon BRD	Director/Board Member	74	1990-11-25
Bhavik Ashokkumar Shah BRD	Director/Board Member	33	2024-08-07
Baptist Bernard Dias BRD	Director/Board Member	76	2024-08-07
Swapnil Madiyar BRD	Director/Board Member	-	2025-05-15
Viiaya Mani BRD	Director/Board Member	-	2025-11-10

Composition of the Board of Directors

Company details: Colinz Laboratories Limited

Colinz Laboratories Ltd.

A/101, Pratik Industrial Estate

400078, Mumbai

http://www.findoc-cll.in

address Colinz Laboratories Limited(COLINZ6)

Generic Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
COLINZ LABORATORIES LIMITED	+0.07%	-0.62%	+74.40%	+78.26%	1.91M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.35%	-2.78%	+14.44%	+59.45%	46.06B
OTSUKA HOLDINGS CO., LTD.	+1.95%	-2.63%	+35.58%	+107.18%	38.29B
ZYDUS LIFESCIENCES LIMITED	-0.58%	-2.88%	+7.29%	+72.39%	11.65B
CIPLA LIMITED	-0.74%	-2.10%	-12.49%	+9.66%	11.51B
KRKA, D. D.	+0.96%	+0.19%	+19.32%	+148.82%	9.17B
GEDEON RICHTER	+0.24%	-1.18%	+23.38%	+35.93%	7.22B
GLENMARK PHARMACEUTICALS LIMITED	-0.93%	-3.15%	+14.15%	+179.80%	7.12B
ONO PHARMACEUTICAL CO., LTD.	+1.16%	-2.50%	+35.63%	-19.52%	7.11B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+0.60%	-3.42%	-44.55%	+12.16%	4.99B
Average	+0.23%	-1.56%	+16.71%	+68.41%	14.31B
Weighted average by Cap.	+0.41%	-2.47%	+17.09%	+74.23%